Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2018/3106852 http://scihub22266oqcxt.onion/10.1155/2018/3106852 C5821982!5821982!29581905     free     free     free       Case+Rep+Hematol 2018 ; 2018 (ä): ä Nephropedia Template TP {{tp|p=29581905|t=2018. Antiphospholipid Antibody Induced by Nivolumab |pdf=|usr=}}{{29581905}} gab.com Text Antiphospholipid Antibody Induced by Nivolumab JO: Case Rep Hematol http://www.kidney.de/pget.php?&tw=1&pmid=29581905 #FOAvip Nivolumab is a monoclonal antibody against the programmed death protein 1 and is used for patients with advanced melanoma. It is associated with potentially immune-related adverse events, including disorders of the skin, GI tract, and the thyroid; these disorders were successfully treated with prednisone and infliximab. Other immunotherapeutic agents were observed to induce the formation of antiphospholipid antibody (APA) including ?-interferon and interleukin-2. We present a case of APA development after the third dose of nivolumab in a 71-year-old male with advanced melanoma. The APA was detected after finding a prolonged aPTT; the lupus anticoagulant assay tested positive. The patient was treated with prednisone but, unfortunately, he expired a few days later. Twit Text FOAVip Antiphospholipid Antibody Induced by Nivolumab ????Case Rep Hematol http://www.kidney.de/pget.php?&tw=1&pmid=29581905 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29581905 #FOAvip English Wikipedia <ref>{{Cite pmid|29581905}}</ref> Antiphospholipid Antibody Induced by Nivolumab #MMPMID29581905 Aburahma A; Aljariri Alhesan N; Elounais F; Abu Sitta E Case Rep Hematol 2018[]; 2018 (ä): ä PMID29581905show ga Nivolumab is a monoclonal antibody against the programmed death protein 1 and is used for patients with advanced melanoma. It is associated with potentially immune-related adverse events, including disorders of the skin, GI tract, and the thyroid; these disorders were successfully treated with prednisone and infliximab. Other immunotherapeutic agents were observed to induce the formation of antiphospholipid antibody (APA) including ?-interferon and interleukin-2. We present a case of APA development after the third dose of nivolumab in a 71-year-old male with advanced melanoma. The APA was detected after finding a prolonged aPTT; the lupus anticoagulant assay tested positive. The patient was treated with prednisone but, unfortunately, he expired a few days later. äAntiphospholipid Antibody Induced by Nivolumab (epmc).pdf DeepDyve Pubget Overpricing